Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Elitek Or Fasturtec Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The expansion during the historic period was driven by the rising use of chemotherapy, the occurrence of TLS complications in the past, the early market authorization of rasburicase, the growth of oncology departments in hospitals, and the increasing prevalence of cancer.
The forecast period’s expansion is driven by an increasing worldwide cancer incidence, the broadening of pediatric oncology initiatives, enhanced early assessment of tumor lysis syndrome (TLS) risk, a rise in specialized oncology facilities, and progress in cancer supportive care. Key developments shaping this market include a stronger emphasis on oncology supportive care, higher adoption for managing tumor lysis syndrome, greater utilization of infusion therapies within hospital settings, the broadening of pediatric cancer treatment options, and enhanced safety measures for chemotherapy administration.
Download A Free Sample Report For Comprehensive Market Insights:
Elitek Or Fasturtec Market Development Factors: Which Trends Are Supporting Demand?
The growing occurrence of leukemia is anticipated to drive the elitek or fasturtec market forward. Leukemia is caused by the excessive multiplication of abnormal white blood cells within the bone marrow, frequently stemming from genetic mutations, environmental influences, or contact with radiation and specific chemicals. An increase in leukemia cases is observed due to older populations, inherited susceptibilities, environmental exposures, and enhanced detection methods. Elitek (Fasturtec) supports leukemia patients by lowering elevated uric acid levels resulting from tumor lysis syndrome (TLS), a complication arising when cancer therapies quickly destroy leukemia cells, discharging significant amounts of uric acid into the bloodstream. For example, in 2024, the American Cancer Society, a US-based non-profit organization focused on cancer advocacy, reported that leukemia cases rose to 62,770, up from 59,610 recorded in 2023. Consequently, the increasing prevalence of leukemia is fueling the elitek or fasturtec market.
Higher healthcare spending is set to boost the elitek or fasturtec market’s growth in the future. Health expenditures cover all costs tied to providing health services, family planning initiatives, nutrition programs, and emergency assistance with a health emphasis. Healthcare spending has risen mainly because a greater incidence of chronic conditions has intensified the need for ongoing therapies, long-term medicines, and frequent medical appointments. These higher expenditures benefit Elitek/Fasturtec by allowing more investment in oncology care and supportive treatments, thereby improving access to advanced therapies that address tumor lysis syndrome and increasing demand for rasburicase among high-risk cancer patients. In May 2025, Statistics Netherlands, a national statistical office based in the Netherlands, reported that the country spent roughly 130.70 billion dollars on healthcare in 2024, representing an increase of 9.79 billion dollars or 8.1 percent compared to 2023. Thus, rising healthcare expenditures are propelling the expansion of the elitek or fasturtec market.
Elitek Or Fasturtec Market Segment Outlook: Which Categories Are Expanding The Fastest?
The elitek or fasturtec market covered in this report is segmented –
1) By Dosage Form: Injectable, Lyophilized Powder
2) By Indication: Tumor Lysis Syndrome (TLS), Other Indications
3) By Patient Type: Pediatric Patients, Adult Patients
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care
Elitek Or Fasturtec Market Transformation Trends: Which Innovations Are Driving Change?
In the elitek or fasturtec market, a notable development involves the growing emphasis on adult applications, particularly for managing tumor lysis syndrome (TLS) in cancer patients. As TLS becomes more common among individuals receiving chemotherapy for aggressive cancers like leukemia, lymphoma, and solid tumors, the need for effective therapies to address this dangerous condition has intensified. Companies operating in this sector are expanding their product utilization beyond pediatric uses, aiming to cater to a broader spectrum of cancer treatments. For example, in October 2023, Sanofi S.A., a pharmaceutical firm based in France, secured FDA approval for Elitek to initially manage plasma uric acid levels in adult patients with leukemia, lymphoma, and solid tumors undergoing anti-cancer therapy that could precipitate TLS and elevated uric acid levels. This regulatory decision was underpinned by pivotal Phase 3 trial findings, which showed that Elitek substantially lowered plasma uric acid levels when compared to the standard treatment of oral allopurinol in adults at risk for TLS, thereby offering a vital therapeutic option for this potentially fatal condition.
Elitek Or Fasturtec Market Key Companies And Competitive Benchmarking
Major companies operating in the elitek or fasturtec market are Sanofi S.A.
Access The Complete Elitek Or Fasturtec Market Report:
Elitek Or Fasturtec Market Geographic Distribution And Regional Opportunities
North America was the largest region in the elitek or fasturtec market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the elitek or fasturtec market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model